Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

K. Choueiri, Toni; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; T. Bourlon, María; Żurawski, Bogdan; Manuel Oyervides-Juárez, Víctor; J. Hsieh, James; Basso, Umberto; Y. Shah, Amishi; Suárez, Cristina; Hamzaj, Alketa; C. Goh, Jeffrey; H. Barrios, Carlos; Eduardo Richardet, Martin; Porta, Camillo; Dario Kowalyszyn, Rubén; P. Feregrino, Juan; Żołnierek, Jakub; Pook, David; R. Kessler, Elizabeth; Tomita, Yoshihiko; Mizuno, Ryuichi; Bedke, Jens; Zhang, Joshua; Maurer, Matthew; Şimşek, Burçin; Ejzykowicz, Flavia; Schwab, Gisela; B. Apolo, Andrea; J. Motzer, Robert

doi:10.1056/nejmoa2026982

Public

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Published in New England Journal of Medicine • Mar 3, 2021

Authors:

Toni K. Choueiri

Thomas Powles

Mauricio Burotto

Abstract

BACKGROUND: The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. METHODS: In this phase 3, randomized, open-label trial, we randomly assigned adults with previously untreated c...

Subject

Cabozantinib

Sunitinib

Nivolumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!